Search

Your search keyword '"Zivkov M"' showing total 40 results
Start Over Author "Zivkov M"
40 results on '"Zivkov M"'

25. Mirtazapine versus amitriptyline in the longterm treatment of depression

Author

Montgomery, S. A., Reimitz, P. -E., and Zivkov, M.

Abstract

Of 580 patients randomly assigned to short-term, double-blind treatment with either mirtazapine, amitriptyline or placebo, a total of 217 patients clinically judged to be responders subsequently continued on the same medication for up to 2 years in the long-term treatment study (mirtazapine, n = 74; amitriptyline, n = 86 and placebo, n = 57). The efficacy of mirtazapine in relapse prevention was seen in an analysis of the first 20 weeks data. Significantly fewer patients relapsed during treatment with mirtazapine compared with placebo (p < 0.05), and a significantly longer time to relapse was shown on the survival analysis. There was a significant advantage for amitriptyline compared with placebo in the first 20 weeks, with fewer patients relapsing. There was a significant advantage for mirtazapine compared with amitriptyline at 20 weeks seen on the survival analysis (p < 0.05). The significant advantage for mirtazapine compared with placebo was also seen in the prophylactic phase of treatment after 20 weeks. At the endpoint there were significantly more patients in the placebo group with a return of symptoms and significantly fewer showing sustained response, Amitriptyline was better than placebo with fewer patients suffering a recurrence of symptoms, but there was no difference from placebo in the proportion of patients with sustained response. Mirtazapine was well tolerated with a side-effect profile similar to that of placebo. The only adverse event reported significantly more frequently on mirtazapine than on placebo was weight gain. Objectively measured weight gain was more frequent with amitriptyline (22 of patients) compared with mirtazapine (13 of patients). Amitriptyline was associated with significantly more adverse events than either mirtazapine or placebo, in particular sedative and anticholinergic side effects. The efficacy of mirtazapine in reducing the risk of relapse and the recurrence of depression, which on some measures showed an advantage compared with amitriptyline, coupled with its improved side-effect profile, commends this antidepressant for the long-term treatment of depression.

Published
1998

39. Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?

Author

Keefe RS, Buchanan RW, Marder SR, Schooler NR, Dugar A, Zivkov M, and Stewart M

Subjects
Adolescent, Adult, Aged, Cognition Disorders psychology, Female, Humans, Male, Middle Aged, Young Adult, Clinical Trials as Topic, Cognition Disorders drug therapy, Nootropic Agents therapeutic use, Schizophrenia drug therapy, Schizophrenic Psychology
Abstract

In light of the number of studies conducted to examine the treatment of cognitive impairment associated with schizophrenia (CIAS), we critically reviewed recent CIAS trials. Trials were identified through searches of the website "www.clinicaltrials.gov" using the terms "schizophrenia AND cognition," "schizophrenia AND neurocognition," "schizophrenia AND neurocognitive tests," "schizophrenia AND MATRICS," "schizophrenia AND MCCB," "schizophrenia AND BACS," "schizophrenia AND COGSTATE," and "schizophrenia AND CANTAB" and "first-episode schizophrenia AND cognition." The cutoff date was 20 April 2011. Included trials were conducted in people with schizophrenia, the effects on cognition were either a primary or secondary outcome, and the effect of a pharmacologically active substance was examined. Drug challenge, pharmacokinetic, pharmacodynamic, or prodrome of psychosis studies were excluded. We identified 118 trials, with 62% using an add-on parallel group design. The large majority of completed trials were underpowered to detect moderate effect sizes, had ≤8 weeks duration, and were performed in samples of participants with chronic stable schizophrenia. The ongoing add-on trials are longer, have larger sample sizes (with a number of them being adequately powered to detect moderate effect sizes), and are more likely to use a widely accepted standardized cognitive battery (eg, the MATRICS Consensus Cognitive Battery) and MATRICS guidelines. Ongoing studies performed in subjects with recent onset schizophrenia may help elucidate which subjects are most likely to show an effect in cognition. New insights into the demands of CIAS trial design and methodology may help increase the probability of identifying treatments with beneficial effect on cognitive impairment in schizophrenia.

Published
2013
Full Text
View/download PDF

40. Imipramine and mirtazapine are less effective than expected.

Author

Pinder RM and Zivkov M

Subjects
Antidepressive Agents, Tricyclic blood, Depressive Disorder blood, Humans, Imipramine blood, Mianserin blood, Mianserin therapeutic use, Mirtazapine, Antidepressive Agents, Tricyclic therapeutic use, Depressive Disorder drug therapy, Imipramine therapeutic use, Mianserin analogs & derivatives
Published
1997
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results